Corporate highlights
Corporate highlights
- Privately-held Montreal-based biotechnology company
- Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets
- Currently having three pre-clinical programs with two INDs expected within the next 12 – 15 months
- Extensive portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology
- Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline
- Established strategic partnerships to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies
- Seasoned management and multi-disciplinary discovery and early-stage development team
- Unencumbered pipeline with the potential for selected strategic partnerships on therapeutic mAbs
